Gastroenterology Research and Practice

Research Article

Steatohepatitis Is Not Associated with an Increased Risk for Fibrosis Progression in Nonalcoholic Fatty Liver Disease

Table 4

(a) Steatohepatitis at baseline biopsy and association with fibrosis progression.


Parameter	OR	95% CI	value	aOR¹	95% CI	value

NASH	0.81	0.27–2.43	0.71	0.97	0.25–3.69	0.96
NAS 5–8	0.88	0.30–2.56	0.81	0.74	0.21–2.62	0.65

¹Adjusted for age at first biopsy, sex, BMI, type 2 diabetes, and time between biopsies. Abbreviations: OR: odds ratio; aOR: adjusted odds ratio; CI: confidence interval; NASH: nonalcoholic steatohepatitis; NAS: NAFLD activity score.

(b) The respective association between NASH at baseline, high NAS at baseline, and fibrosis progression per se, with mortality using Cox regression.


Parameter	HR	95% CI	value	aHR¹	95% CI	value

NASH	1.43	0.55–3.69	0.46	0.97	0.20–4.67	0.97
NAS 5–8	1.02	0.41–2.54	0.97	0.46	0.12–1.69	0.24
Fibrosis progression	2.10	0.87–5.09	0.10	2.83	0.99–8.05	0.051

¹Adjusted for sex, age, BMI, type 2 diabetes at first biopsy, and time between biopsies. Abbreviations: OR: odds ratio; aOR: adjusted odds ratio; CI: confidence interval; NASH: nonalcoholic steatohepatitis; NAS: NAFLD activity score.